1Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of cabl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia [J]. Nature, 1983, 306(5940) :277.
2Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products[J]. Science, 1990, 247(4946):1079.
3ODwyer ME, Mauro MJ, Druker BJ. Recent advancements in the treatment of chronic myelogenous leukemia [J]. Annu Rev Med,2002,53:369.
4Buchdunger E, OReilly T, Wood J. Pharmacology of imatinib (STI571) [J]. Eur J Cancer, 2002 ,38 (Suppl 5) :S28.
5Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors [J]. J pharmacol Exp Ther, 2000,295(1) :139.
6Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells [J]. Blood, 1997,90(9) :3691.
7Carroll M, Ohno-Jones S, Tamura S, et al. GP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL,TEL-ABL, and TEL-PDGFR fusion proteins [J]. Blood, 1997,90(12) :4947.
8Dan S, Naito M, Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR- ABL tyrosine kinase, CGP 57148[J]. Cell Death Differ, 1998, 5(8) :710.
9Thiesing JT, Ohno-Jones S, Kolibaba KS, et al. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells [J]. Blood,2000,96(9) :3195.
10La Rosee P, Johnson K, O Dwyer ME, et al. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia [J]. Exp Hematol, 2002,30 (7) :729.
